3 results
Primary Objective is to evaluate the long-term safety of sirukumab in subjects with RA who are refractory to DMARDs or anti-TNF* agents.The secondary objectives are to observe the following long-term effects of sirukumab in subjects with RA who are…
The primary objective is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of RA in subjects with active RA who are refractory to an anti-TNF Alpha agent. The secondary objectives are to assess the following…
Primary objectivesPhase ITo establish the safety and tolerability of fractionated intravenous (i.v.) administrations of 177Lu-3BP-227 in subjects with unresectable, locally advanced or metastatic cancers expressing NTSR1.Phase IITo estimate ORR of…